{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:12:51Z","timestamp":1790766771939,"version":"4.1.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamaoncol.2022.2253","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T11:32:50Z","timestamp":1656588770000},"page":"1169","source":"Crossref","is-referenced-by-count":76,"title":["Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Tiantian","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Hunan Cancer Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Provincial Cancer Center, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"She","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Guan","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Hou","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi220027r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9698","key":"coi220027r2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer.","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"coi220027r3","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future.","volume":"27","author":"Monk","year":"2016","journal-title":"Ann Oncol"},{"issue":"13","key":"coi220027r4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"coi220027r5","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives.","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi220027r6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"coi220027r7","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi220027r8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"coi220027r9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","article-title":"Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.","volume":"19","author":"Lan","year":"2018","journal-title":"Lancet Oncol"},{"issue":"35","key":"coi220027r10","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.","volume":"31","author":"Naumann","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"coi220027r11","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi220027r12","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial.","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi220027r13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi220027r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1226","article-title":"Efficacy and safety of apatinib plus vinorelbine in patients with wild-type advanced non\u2013small cell lung cancer after second-line treatment failure: a nonrandomized clinical trial.","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"coi220027r15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2020.02.013","article-title":"Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: a single-arm, open-label, phase II trial.","volume":"130","author":"Zheng","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"coi220027r16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"issue":"21","key":"coi220027r17","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2007.11.5113","article-title":"Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?","volume":"25","author":"van Heeckeren","year":"2007","journal-title":"J Clin Oncol"},{"issue":"31","key":"coi220027r18","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/JCO.2016.68.8663","article-title":"Is treatment-emergent toxicity a biomarker of efficacy of apatinib in gastric cancer?","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2793857\/jamaoncology_wang_2022_oi_220027_1660581510.42847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:05:48Z","timestamp":1660907148000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2793857"}},"subtitle":["The APPROVE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.2253","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}